UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K

 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

DecemberFor 31,the 2022fiscal year ended 

December 31, 2023

 TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 000-55661

EOS INC.

(Exact name of registrant as specified in its charter)

Nevada		30-0873246
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

5F-1, No.5, Qingdao E. Rd., Zhongzheng Dist., 

4F-1, No.5, Qingdao E. Rd., Zhongzheng Dist.,

Taipei City 100008 Taiwan (Republic of China)

(Address of principal executive offices, Zip Code)

+8862-2586-8300

2586

8300

(Registrant’s telephone number, including area code)

Securities Registered Pursuant to Section 12(b) of the Act: None

Securities Registered Pursuant to Section 12(g) of the Act: Common Stock $.001 par value

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	x	Smaller reporting company	x
Emerging Growth Company	x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).

☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes

☒¨

☐x

The aggregate market value of the voting and non-voting common equity held by non-affiliates was $24,580,140 computed by reference to the closing price of the registrant’s common stock as quoted on the OTCQB maintained by OTC Markets, Inc. on June 30, 2022 (which was $6.50 per share). For purposes of the above statement only, all directors, executive officers and 10% shareholders are assumed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for any other purpose.

As of March 2

278

, ~~2023, there were~~ 202

~~183,781,560~~4

, there were 604,781,560 shares of common stock, par value $0.001 issued and outstanding.

0.001

issued and outstanding.

Documents Incorporated by Reference: None

TABLE OF CONTENTS

PART I
Item 1.	Business	34
Item1A.	Risk Factors	607
Item1B.	Unresolved Staff Comments	607
Item 2.	Properties	607
Item 3.	Legal Proceedings	607
Item 4.	Mine Safety Disclosures	607
PART II
Item 5.	Market for Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	608
Item 6.	[Reserved]	810
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	910
Item7A.	Quantitative and Qualitative Disclosures about Market Risk	17
Item 8.	Financial Statements and Supplementary Data	17
Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	1918
Item9A.	Controls and Procedures	1918
Item9B.	Other Information	2019
Item9C	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	2019
PART III
Item10.	Directors, Executive Officers and Corporate Governance	2019
Item11.	Executive Compensation	2423
Item12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	2524
Item13.	Certain Relationships and Related Transactions and Director Independence	2524
Item14.	Principal Accountant Fees and Services	2625
PART IV
Item15.	Exhibits, Financial Statement Schedules	2726
Item 16.	Form 10-K Summary	2726
SIGNATURES		2827

FORWARD LOOKING STATEMENTS

Forward-Looking Statements

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including: any projections of earnings, revenues or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new products, services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. Forward-looking statements may include the words “may,” “might,” “will,” “will likely result,” “would,” “should,” “estimate,” “intend,” “continue,” “believe,” “expect,” “plan,” “project,” “forecast,” “anticipate,” “seek,” “continue,” “target” or the negative of such terms or other similar expressions. The ultimate correctness of these forward-looking statements is dependent upon a number of known and unknown risks and events and is subject to various uncertainties and other factors that may cause our actual results, performance or achievements to be different from any future results, performance or achievements expressed or implied by these statements.

The following important factors, among others, could affect our future results and events, causing those results and events to differ materially from those views expressed or implied in our forward-looking statements: our ability to continue as a going concern absent new debt or equity financings; our ability to successfully remediate material weaknesses in our internal controls; our ability to reach research and development milestones as planned and within proposed budgets; our ability to control costs; our ability to successfully implement our expansion strategies; our current reliance on substantial debt financing that we currently are unable to repay in cash; our ability to obtain adequate new financing; our ability to successfully develop PRP, our lead product candidate; our ability to successfully develop and market our technologies; our ability to obtain and maintain patent protection; our ability to recruit employees and directors with accounting and finance expertise; our dependence on third parties for services; our dependence on key executives; the impact of government regulations, including U.S. Food and Drug Administration regulations; the impact of any future litigation; the availability of capital; changes in economic, business and competitive conditions; and other risks. Any one or more of such risks and uncertainties could have a material adverse effect on us or the value of our common stock.

All forward-looking statements included in this Form-10-K are made only as of the date of this Annual Report or as of the date indicated. We do not undertake any obligation to, and may not, publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or which we hereafter become aware of, except as required by law. New risks and uncertainties arise from time to time and we cannot predict these events or how they may affect us. When considering these risks, uncertainties and assumptions, you should keep in mind the cautionary statements contained in this Annual Report and any documents incorporated herein by reference. You should read this Annual Report and the documents that we incorporate by reference into this Annual Report completely and with the understanding that our actual future results may be materially different from what we expect. All forward-looking statements attributable to us are expressly qualified by these cautionary statements.

~~PART I~~3

~~Item 1. Business.~~PA

RT I

tem 1. Business.

Description of Business

General Information

EOS Inc. (“we,” “us,” “our,” or the “Company”) was incorporated in the State of Nevada on April 3, 2015.

On or about November 18, 2016, the Company formed EOS INC. TAIWAN BRANCH, a Taiwanese corporation (“EITB”) and the Company owns 100% of EITB.

On May 3, 2017, the Company entered into and closed a Share Purchase and Sale Agreement (the “Purchase Agreement”) with Emperor Star International Trade Co., Ltd., (“Emperor Star”), to acquire all of the issued and outstanding shares of Emperor Star in consideration of $30,562 in cash. As a result of the transaction, Emperor Star became the Company’s wholly owned subsidiary. Upon consummation of the transaction, the Company has assumed the business of Emperor Star and ceased to be a shell company. Yu-Hsiang Chia currently serves as the officer and director of Emperor Star. Emperor Star was incorporated on November 16, 2015 under the laws of Taiwan and is in the business of marketing and distributing various consumer products, including nutrition supplements and skin care products.

Yu-Hsiang Chia currently serves as the officer and director of Emperor Star. On May 26, 2020, EOS Inc. increased its investment in Emperor Star by $134,004 (NTD$4,000,000). The Company also received contributions to Emperor Star from non-controlling interests in the amount of $33,398 (NTD$1,000,000). As a result, the Company owns 83% equity interest of Emperor Star as of June 30, 2020, which is no longer a wholly-owned subsidiary.

On September 20, 2018, the Company set up another wholly-owned subsidiary, EOS International Inc. (“EOS(BVI)”), under the laws of British Virgin Islands. EOS(BVI) is in the business of marketing and distribution of various products, including nutrition supplements, skin care products, and water purifiers.

On March 1, 2019, EOS(BVI) set up a wholly-owned subsidiary, Shanghai Maosong Co., Ltd (“Maosong”), under the laws of People’s Republic of China. Maosong is in the business of marketing and distribution of various products, including nutrition supplements, skin care products, and water purifiers in China.

On June 2, 2020, EOS(BVI) 83.33% owner, and Shanghai Qifan Qiye Management Co., Ltd. (“Qifan”) 16.67% owner of Maosong resolute to change the registered capital of Maosong to RMB 1,200,000,000 (1.2 billion) and that EOS to contribute certain Intellectual Property as registered capital of Shanghai Maosong. Intellectual Property owned by EOS International Inc was valued at RMB 1,000,000,000 (1 billion) and Intellectual Property owned by Qifan was valued at RMB 200,000,000 (200 million).

On July 13, 2021, EOS(BVI), MaoSong, and Qifan entered into a Shareholder Agreement where Qifan (i) delegate its 16.67% equity voting rights, powers, or benefits in Maosong to EOS(BVI); (ii) grant EOS(BVI) an irrevocable, unconditional, exclusive option to purchase Maosong’s equity interest; (iii) the right to receive any proceeds from the Maosong’s Equity Interest; (iv) pledge its existing or any prospective Maosong equity interest to EOS Int’l; as a result EOS(BVI) retains 100% control of MaoSong and the 16.67% noncontrolling interest are consolidated.

Corporate Actions

On August 18, 2018 the Company filed a Certificate of Amendment to its Articles of Incorporation in which the Company elected not to be governed by 78.411 to 78.444, inclusive, of the Nevada Revised Statutes.

On March 16, 2021, the Company filed a Certificate of Change to the Company’s Articles of Incorporation to increase its authorized common stock from 75,000,000 to 575,000,000.

On March 31, 2021, the Company’s board of directors and stockholders authorized a reverse stock split of its outstanding common stock at a ratio of 1-for-1000 without any change in the par value per share which became effective on April 7, 2021 upon approval by FINRA.

On August 19, 2021, the Company filed a Certificate of Designation to establish a Series A preferred stock. The number of shares designated for the class of stock is 5,000,000 shares. The holders of these shares are entitled to 1,000 votes per each share of Series A stock owned.

December 1

2023

the Company filed a Certificate of Change to the Company’s Articles of Incorporation to increase its authorized common stock from

75,000,000 to

1,000

,000,000.

Business Overview

We are a distributor of various consumer products. Our goal is to source and bring to our channel partners the most innovative products which aims to improve quality of life, achieve optimal health, and promote green energy.

InDuring ~~July 2022, we commenced to market, promote and sell~~ the ~~ginsenosides supplements manufactured by Wellhead Biological Technology Corp. (“Wellhead”), which is headquartered in Taiwan and specializes in~~ year

~~ginsenoside~~, we

~~R&D~~ ~~and production.~~ continued

to market, promote and sell the ginsenosides supplements manufactured by Wellhead Biological Technology Corp. (“Wellhead”), which is headquartered in Taiwan and specializes in ginsenoside R&D and production.

Ginsenosides are the active components in ginseng, and Wellhead owns the patented enzymatic degradation technology to manufacture and extract the pure rare ginsenosides which is deemed highly valuable in the space of Chinese medicines and healing. Ginsenosides are used to improve health and boost physical strength.

The ginsenosides supplements that we promote and sell are being named “Bodywafer” and the products are customized and manufactured specifically for EOS Inc.

We acquire the products from Wellhead and sell directly to our channel partners who will recognize the needs of their target customers in various regions in Asia, such as People’s Republic of China (“PRC”), Singapore and Malaysia. We also provide comprehensive sales training to our channel partners through onsite seminars and online webinars to effectively market our products.

On March 2, 2020, the Company, A-Best, and Ing-Ming Lai, a Taiwanese individual and the majority shareholder of A-Best (collectively, the “Parties”) entered into a strategic alliance agreement (the “Strategic Alliance Agreement”), pursuant to which the Parties redefined their cooperation with respect to the sales and distribution of A-Best’s micro-ceramic speakers. In accordance with the Strategic Alliance Agreement, A-Best, Mr. Ing-Ming Lai and the Company terminated the Investment Cooperation Agreement dated January 12, 2019 entered by and among the Parties and as a result the Company agreed to return 20% of the equity interest in A-Best to Mr. Ing-Ming Lai, which was valued at approximately $35,142 by the Parties.

Furthermore, subject to the terms and conditions of the Strategic Alliance Agreement, A-Best has granted the Company the exclusive sale and distribution right of A-Best’s micro-ceramic speakers in the world for one (1) year (the “Term”), which may be renewed with mutual consent of the Parties two months prior to the expiration of the Term, while A-Best retains its own right to sell and distribute the micro-ceramic speakers on its own. In consideration for the exclusive distribution right of A-Best’s speakers under the Strategic Alliance Agreement, the Company agreed to have A-Best keep the Company’s 10,000,000 shares of common stock, par value $0.001 per share, issued under the Investment Cooperation Agreement and the Company may keep the revenue and profits generated from the sale of A-Best speakers until the total revenue from such speakers reaches $15 million U.S. dollars. This Strategic Alliance Agreement contains A-Best’s and Mr. Ing-Ming Lai’s joint representation regarding their intellectual property rights to A-Best ceramic speakers.

On March 2, 2020, the Company returned 20% equity interest in A-Best to Mr. Ing-Ming Lai pursuant to the Strategic Alliance Agreement.

On April 12, 2021, the Company, A-Best, and Ing-Ming Lai signed the Termination Agreement, and Mr. Ing-Ming Lai returned the 10,000 EOSS common shares (originally 10,000,000 shares prior to EOS Inc. effecting a one-for-one thousand reverse split of the company stock) to EOS Inc. which was issued under the Investment Cooperation Agreement.

Investment Cooperation Agreement with AsiaSonic

On August 28, 2021, the Company and AsiaSonic International Industrial Co., LTD. (“AsiaSonic”), a corporation formed under the laws of Taiwan, ROC, entered into Investment Cooperation Agreement, and Business and Management Agreement, pursuant to which, subject to the terms and conditions therein, the Company and AsiaSonic shall cooperate in the sales and distribution of AsiaSonic’s automotive peripherals and accessories globally by acquisition of Fifty One percent (51%) equity interest of AsiaSonic.

In accordance with the Agreements and in consideration for the cooperation, the Company shall issue to AsiaSonic’s shareholders and designees One Million Five Hundred Thousand (1,500,000) restricted shares of its common stock in exchange for the equivalent value of Fifty One percent (51%) of the total issued shares of AsiaSonic. According to the Agreements, AsiaSonic shall assist and provide training and marketing materials to the Company for the distribution and sale of its products. AsiaSonic shall continue to appoint the officers or managers and be in charge of the business operations; and the Company may appoint a director who is entitled to one vote on the Board meetings or to express consent or dissent on Board resolutions.

On March 30, 2023, the Company and AsiaSonic entered into a Termination Agreement to terminate the Investment Cooperation Agreement and Business and Management Agreement. The decision is made primarily due to additional time required to mutually agree on terms with respect to sales strategies and business operations.

Future Prospect

We will take a strategic move in the coming future. We will evolve into a resource integration service provider that integrates the world’s leading biotechnology and products. The company focuses on creating new models of personal and family consumption so that consumers can obtain brand-new experiences and additional benefits in the process of purchasing products and consumption and additional value. The company readjusts the profit structure model of the industrial chain with the exclusive planning of corporate cooperation plans so that the public can obtain more stable and rapid sales growth opportunities through good consumer experience and word-of-mouth transmission.

EOS provides comprehensive enterprise marketing solutions, including training

services, sales system establishment, operations management, sales strategy and

other optimization services. It has complete video conferencing and various sales

courses to quickly analyze the competitive advantages of products and strengthen

the core technology of products.

Through the innovative asset empowerment

computing system of EOS, we can design the most suitable marketing plan for

customers, upgrade and empower the sales team, quickly grow the number of

people in the organization and achieve the goal of doubling growth

EMPLOYEES

As of March 27, 2023, we employ nine full-time and no part-time employees. In addition to our employees, we engage key consultants and utilize the services of independent contractors to perform various services on our behalf. Some of our executive officers and directors are engaged in outside business activities that we do not believe conflict with our business. Over time, we may be required to hire additional employees or engage independent contractors to execute various projects that are necessary to grow and develop our business. These decisions will be made by our officers and directors, if and when appropriate.202

, we employ

full-time and no part-time employees. In addition to our employees, we engage key consultants and utilize the services of independent contractors to perform various services on our behalf. Some of our executive officers and directors are engaged in outside business activities that we do not believe conflict with our business. Over time, we may be required to hire additional employees or engage independent contractors to execute various projects that are necessary to grow and develop our business. These decisions will be made by our officers and directors, if and when appropriate.

CORPORATE INFORMATION

Our principal executive office is presently located at ~~4F-1, No.5, Qingdao E. Rd., Zhongzheng Dist., Taipei City 100008 Taiwan (Republic of China).~~

Our telephone number is +8862-2586-8300. Our website is eosinc999.us. Our website’s information is not, and will not be deemed, a part of this Annual Report or incorporated into any other filings we make with the SEC.

F-1, No.5, Qingdao E. Rd., Zhongzheng Dist., Taipei City 100008 Taiwan (Republic of China).

AVAILABLE INFORMATION

Copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other documents that we will file with or furnish to the SEC will be available free of charge by sending a written request to our Corporate Secretary at our corporate headquarters. Additionally, the documents we file with the SEC are or will be available free of charge at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Other information on the operation of the Public Reference Room may be obtained by calling the SEC at (800) SEC-0330. The SEC maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The SEC’s website is www.sec.gov.

~~Item 1A. Risk Factors.~~I

tem 1A. Risk Factors.

Not applicable for smaller reporting companies.

~~Item 1B. Unresolved Staff Comments.~~I

tem 1B. Unresolved Staff Comments.

None.

~~Item 2. Properties.~~I

Wetem ~~do not own any real property~~2. ~~Our principal executive office is presently located at 4F-1, No~~Properties.5, Qingdao E. Rd., Zhongzheng Dist., Taipei City 100008 Taiwan (Republic of China). EITB and Emperor Star operate from this Taipei location. Emperor Star and EITB entered into the office leases which commenced on February 6, 2023 and will end on December 31, 2023. The office occupies approximately 2579.78 square feet and the average amount of office rent (including the maintenance fees) is approximately $2,000 per month.

~~Item~~We 3.do ~~Legal~~not ~~Proceedings~~own any real property. Our principal executive office is presently located at

F-1, No.5, Qingdao E. Rd., Zhongzheng Dist., Taipei City 100008 Taiwan (Republic of China). EITB and Emperor Star operate from this Taipei location. Emperor Star and EITB entered into the office leases which commenced on

December

, 2023 and will end on

May

31, 202

. The average amount of office rent (including the maintenance fees) is approximately $2,

293

per month.

tem 3. Legal Proceedings.

We are not currently involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, or proceeding by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our Company or our subsidiary, threatened against or affecting our Company, our common stock, our subsidiary or of our companies or our subsidiary’s officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

~~Item 4. Mine Safety Disclosures~~I

tem 4. Mine Safety Disclosures

Not applicable

~~PART II~~7

~~Item 5. Market for Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.~~P

~~Our~~ART common stock is currently quoted on the OTCQB under the symbol “EOSS.” There has not been any significant trading to date in the Company’s common stock. The table below presents the high and low bid for our common stock for each quarter for the years ended December 31, 2022 and 2021. These prices reflect inter-dealer prices, without retail markup, markdown, or commission, and may not represent actual transactions.II

	High		Low
Year ended December 31, 2022
1st Quarter	$	6.50	$	6.50
2nd Quarter	$	6.50	$	6.50
3rd Quarter	$	7.01	$	6.50
4th Quarter	$	10.01	$	7.01
Year ended December 31, 2021
1st Quarter	$	4.21	$	3.75
2nd Quarter	$	18.00	$	2.25
3rd Quarter	$	1.01	$	1.01
4th Quarter	$	25.00	$	25.00

6tem 5. Market for Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Our common stock is currently quoted on the OTCQB under the symbol “EOSS.” There has not been any significant trading to date in the Company’s common stock. The table below presents the high and low bid for our common stock for each quarter for the years ended December 31, 2023 and 2022. These prices reflect inter-dealer prices, without retail markup, markdown, or commission, and may not represent actual transactions.

	High		Low
Year ended December 31, 2023
1st Quarter	$	9 . 0 0	$	9 . 0 0
2nd Quarter	$	3.87	$	3.87
3rd Quarter	$	3.65	$	3.65
4th Quarter	$	0.3 0	$	0.3 0

Year ended December 31, 2022
1st Quarter	$	6.50	$	6.50
2nd Quarter	$	6.50	$	6.50
3rd Quarter	$	7.01	$	6.50
4th Quarter	$	10.01	$	7.01

Security Holders

There were approximately ~~373 holders of record of our common stock as of March 27, 2023.~~

551

holders of record of our common stock as of

March 31, 2024

Common Stock

Each share of our common stock entitles the shareholder one vote on any and all matters such shareholder is entitled to vote at a shareholders’ annual or special meeting. There are no cumulative voting rights, which mean that the shareholder or shareholders owning 50% of the issued and outstanding shares in our capital stock can elect the entire board of directors. Therefore, any shareholder or shareholders, cumulatively with less than 50% of the voting power, cannot elect any director to the board of directors on their won. Pursuant to the provisions of Section 78.320 of the Nevada Revised Statues (the “NRS”), at least a majority of the outstanding shares of capital stock entitled to vote must be present, in person or by proxy, at any meeting in favor of the action exceeds the number of votes cast in opposition to the action, provided, however, that directors may be elected by a plurality of the votes of the shares present at the meeting and entitled to vote. Certain fundamental corporate changes, such as the liquidation and business combination, require the approval of holders of a majority of the outstanding shares entitled to vote.

Holders of our common stock have no pre-emptive rights nor conversion rights. There are no redemption or sinking fund provisions applicable to our common stock.

Preferred Stock

As of March ~~27, 2023~~

~~, the outstanding number of shares of our Series A preferred stock was 2,000,000. Each share~~ 19

, 202

, the outstanding number of shares of our Series A preferred stock was

00,000. Each share

is entitled to 1,000 votes of common stock without dividend rights.

Dividends

The holders of our common stock are entitled to receive dividends on a pro rata based on the number of shares held, when and if declared by our Board of Directors, from funds legally available for that purpose. NRS Section 78.288 prohibits us from declaring dividends where, after giving effect to the distribution of the dividend we would not be able to pay our debts as they become due in the normal course of business; or except as may be allowed by our Articles of Incorporation, our total assets would be less than the sum of our total liabilities plus the amount that would be needed, if we were to be dissolved at the time of the distribution, to satisfy the preferential rights upon dissolution of stockholders who may have preferential rights and whose preferential rights are superior to those receiving the distribution. We do not, however, intend to pay any dividends in the foreseeable future and currently intend to retain all future earnings to finance our business.

Our shareholders are not entitled to preference as to dividends or interest; pre-emptive rights to purchase new issues of shares; preference upon liquidation; or any other special rights or preferences.

There are no restrictions on dividends under any loan or other financing arrangements.

7We paid no dividends on our common stock in the fiscal year of 202

We paid no dividends on our common stock in the fiscal year of 2022. We do not have a policy of paying regular dividends and do not expect to pay any dividends on our common stock in the foreseeable future. We currently intend to retain any future earnings for our business. The payment of any future dividends on our common stock will be determined by our Board of Directors and will depend on business conditions, our financial earnings and other factors.3

. We do not have a policy of paying regular dividends and do not expect to pay any dividends on our common stock in the foreseeable future. We currently intend to retain any future earnings for our business. The payment of any future dividends on our common stock will be determined by our Board of Directors and will depend on business conditions, our financial earnings and other factors.

Outstanding Stock Options, Warrants and Convertible Securities

We have no outstanding stock options, warrants or convertible securities as of December 31, ~~2022~~2023.

Recent Sales of Unregistered ~~Securities~~

and free

Securities

Common Stock

On ~~May~~April 1912, ~~2022~~2021, A-Best, and Mr. Ing-Ming Lai entered into a termination agreement (the ~~Company~~“Termination ~~issued~~Agreement”) ~~3,601,306~~to ~~shares~~terminate the agreement of ~~restricted~~Strategic ~~common~~Alliance ~~stock~~Agreement todated ~~non-employees~~March 2, 2020. In the ~~amount~~agreement, isIng-Ming ~~recorded~~Lai ashas ~~deferred~~proceeded ~~(unearned)~~to ~~compensation~~return a total of ~~$38~~ 10,~~534,~~000 ~~due~~shares toin ~~the~~EOS ~~service~~Inc, ~~has~~back ~~not~~to ~~been~~the ~~started~~Company.

On May 19, 2022, the Company issued 115,000 shares of restricted common stock to non-employees as compensation in the amount of $1,231.

On August 18, 2021, the Company completed and closed a series of transactions to reorganize the Company’s structure and to develop its business by acquiring certain minority control interest of its subsidiary and intellectual properties. Pursuant to the Intellectual Property Transfer Agreement, the Company to issue 75,000,000 shares of Common Stock to the transferors for the intellectual properties in consideration of the transfer. Pursuant to the Shareholders’ Agreement of Shanghai Maosong Trading Co., Ltd and Equity Pledge Agreements, the Company to issue 15,000,000 shares of Common Stock to the transferors for the minority controlling interests of its subsidiary. Upon completion of the transactions above, EOS International Inc became a wholly controlled subsidiary of the Company.

On July 8, 2021, the Company issued 75,000,000 shares of Common Stock at $0.001 per share to convert outstanding debt owed to Co-Innovation Group Limited in the amount of $75,000.

On July 8, 2021, the Company issued 15,000,000 shares of Common Stock at $0.001 per share to convert outstanding debt owed to World Capital Holding Ltd in the amount of $15,000.

On ~~April~~August 1218, 2021, ~~A-Best,~~the Company completed and ~~Mr.~~closed ~~Ing-Ming~~a ~~Lai~~series ~~entered~~of ~~into~~transactions ato ~~termination~~reorganize ~~agreement~~the (Company’s structure and to develop its business by acquiring certain minority control interest of its subsidiary and intellectual properties. Pursuant to the ~~“Termination~~Intellectual Property Transfer Agreement”), the Company to ~~terminate~~issue 75,000,000 shares of Common Stock to the ~~agreement~~transferors for the intellectual properties in consideration of ~~Strategic~~the ~~Alliance~~transfer. Pursuant to the Shareholders’ Agreement ~~dated~~of ~~March~~Shanghai 2,Maosong ~~2020~~Trading Co., InLtd and Equity Pledge Agreements, the ~~agreement~~Company to issue 15,000,000 ~~Ing-Ming~~shares ~~Lai~~of ~~has~~Common ~~proceeded~~Stock to ~~return~~the atransferors ~~total~~for the minority controlling interests of ~~10,000~~its ~~shares~~subsidiary. inUpon completion of the transactions above, EOS International Inc, ~~back~~became toa wholly controlled subsidiary of the Company.

On May 19, 2022, the Company issued 3,601,306 shares of restricted common stock to non-employees, the amount is recorded as deferred (unearned) compensation of $38,534, due to the service has not been started.

On May 19, 2022, the Company issued 115,000 shares of restricted common stock to non-employees as compensation in the amount of $1,231.

On September 7, 2023, the Company issued 21,000,000 of freely tradable common stock to non-employees as compensation in the amount of $41,019.

On December 5, 2023, the Company issued 345,000,000 shares of Common Stock at fair value $0.00122 per share to Co-Innovation Group Limited to convert outstanding debt owed to Mr. Yu-Cheng YANG in the amount of $420,900.

On December 18, 2023, the Company issued 55,000,000 shares of Common Stock at fair value $0.00122 per share to non-employees to convert outstanding debt owed to Mr. Yu-Cheng YANG in the amount of $67,100.

Warrants

On February 3, 2022, the Company granted the issuance of warrants to purchase 200,000 shares of the Company’s common stock at an exercise price of $2 per share with an expiration date of December 22, 2027 to a consultant or its designees as compensation. The warrants were fully vested upon issuance.

~~Item 6. [Reserved]~~9

~~Item~~tem 76. ~~Management’s Discussion and Analysis of Financial Condition and Results of Operations.~~[Reserved]

tem 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward Looking Statements

Some of the statements contained in this Form 10-K that are not historical facts are “forward-looking statements” which can be identified by the use of terminology such as “estimates,” “projects,” “plans,” “believes,” “expects,” “anticipates,” “intends,” or the negative or other variations, or by discussions of strategy that involve risks and uncertainties. We urge you to be cautious of the forward-looking statements, that such statements, which are contained in this Form 10-K, reflect our current beliefs with respect to future events and involve known and unknown risks, uncertainties, and other factors affecting our operations, market growth, services, products, and licenses. No assurances can be given regarding the achievement of future results, as actual results may differ materially as a result of the risks we face, and actual events may differ from the assumptions underlying the statements that have been made regarding anticipated events. Factors that may cause actual results, our performance or achievements, or industry results, to differ materially from those contemplated by such forward-looking statements include without limitation:

Our ability to attract and retain management and key employees;

Our ability to generate customer demand for our products;

The intensity of competition; and

General economic conditions.

All written and oral forward-looking statements made in connection with this Form 10-K that are attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given the uncertainties that surround such statements, you are cautioned not to place undue reliance on such forward-looking statements.

Business Overview

~~ginsenoside~~, we co

~~R&D~~ntinued ~~and production.~~

~~Ginsenosides~~to ~~are the active components in ginseng~~market, ~~and~~promote ~~Wellhead owns the patented enzymatic degradation technology to manufacture~~ and ~~extract~~sell the ~~pure rare~~ ginsenosides ~~which~~supplements ismanufactured ~~deemed~~by ~~highly~~Wellhead ~~valuable~~Biological inTechnology ~~the space of Chinese medicines and healing~~Corp. ~~Ginsenosides are used to improve health and boost physical strength.~~(“Wellhead”)

The ginsenosides supplements that we promote and sell are being named “Bodywafer” and the products are customized and manufactured specifically for EOS Inc.

Results of Operation

The following presents the consolidated result of the Company for the year ended December 31, ~~2022~~2023 compared to the year ended December 31, ~~2021~~2022.

Net sales

Net sales were $~~652~~296,~~547~~852 for year ended December 31, ~~2022~~2023, representing ana ~~increase~~decrease of $~~134~~355,~~060~~695, or 2655%, as compared to $~~518~~652,~~487~~547 for the year ended December 31, ~~2021~~2022. The ~~increase~~decrease was primarily due to the ~~increase~~consumer indemand ~~sales~~for ofthe ~~nutrition~~products ~~supplement~~falling and the company phased out some old products such as automobile carbon reduction machines.

Cost of sales

Cost of sales was $~~365,282 for the year ended December 31, 2022, representing an increase of $52,331 or 17%, as compared to $312,951 for the year ended December 31, 2021.~~

~~The increase was primarily due to the cost of the variety products sold.~~102

975

 for the year ended December 31, 2023, representing a 

crease

 of $

262

or

%, as compared to $365,282 for the year ended December 31, 2022. 

The decrease was primarily due to the 

decrease in sales

Gross profit

Gross profit was $~~287~~193,~~265~~877 for the year ended December 31, ~~2022~~2023, compared to $~~205~~287,~~536~~ 265 for the same period in 2021. Gross profit as a percentage of net sales was 44% for the year ended December 31, 2022, compared to 40% in the same period in 2021. The increase was primarily due to the increase in sales of nutrition supplement with higher margin.202

. Gross profit as a percentage of net sales was

% for the year ended December 31, 2023, compared to 4

% in the same period in 202

. The increase was primarily due to

the

sales of nutrition supplement with higher margin.

Selling, general and administrative expenses

Selling, general and administrative expenses consist primarily of office rent, salary and related costs for personnel and facilities, and professional service fees. Selling, general and administrative expenses were $2966,~~208,876~~486 for the year ended December 31, ~~2022~~2023, representing ana increase of $934,260 or 73%, as compared to $1,274,616 for the year ended December 31, 2021. The increase was primarily due to impairment of security deposits recognized for year ended December 31, 2022.

~~Income (loss) from operations~~de

~~Loss~~crease ~~from operations was $1,921,611 for the year ended December 31, 2022 compared to loss from operations~~ of $1,~~069~~242,~~080~~390 ~~for the year ended December 31, 2021, representing an increase of $852,531~~ or ~~80%. The increase was primarily due to impairment of security deposits.~~

%, as compared to $2,208,876 for the year ended December 31, 2022. The

crease was primarily due to

no significant

impairment

s in assets be recorded

for year ended December 31, 2023.

oss from operations

Loss from operations was $772,609 for the year ended December 31, 2023 compared to loss from operations of $1,921,611 for the year ended December 31, 2022, representing

crease of $1,149,002

%. The

crease was primarily due to no significant impairments in assets be recorded for year ended December 31, 2023.

Other income (expense)

Other ~~expenses~~income were $641 for the year ended December 31, 2022, reflecting a decrease of $15,252, or 96%, compared to other expenses of $15,893 for the year ended December 31, 2021. The decrease was mainly attributable tow

~~additional currency exchange~~ as

~~gain~~ $140,673 for the year ended December 31, 2023, a turnaround from other expense of $641 for the year ended December 31, 2022. The turnaround was mainly attributable certain bad debts were recovered during the year of 2023 and recorded as other income.

recognized for the year ended December 31, 2021

and $nil for the year ended December 31, 2022.

Net loss

As a result of the above factors, our net loss was $1631,~~912,159~~936 for the year ended December 31, ~~2022~~2023, as compared to net loss of $1,~~101~~912,~~565~~159 for the year ended December 31, ~~2021~~2022, representing an ~~increase of $810,594 or 74%.~~ improvement

of $1,280,223 or 

%.

Liquidity and Capital Resources

Cash and cash equivalents were $1814,~~169~~307 at December 31, ~~2022~~2023 and $2418,~~141~~169 at December 31, ~~2021~~2022. Our total current assets were $~~425~~487,~~916~~319 at December 31, ~~2022~~2023, as compared to $2425,~~037,901~~916 at December 31, ~~2021~~2022. Our total current liabilities were $1,~~266~~494,~~234~~230 at December 31, ~~2022~~2023, as compared to $~~792~~1,~~118~~266,234 at December 31, ~~2021~~2022.

We had a working deficit of $1,~~245~~006,~~783~~911 on December 31, 2023, compared to the working deficit of $840,318 on December 31, 2022. The widening in the working deficit was primarily attributable to the increase in certain other payables.

~~194~~Net cash used in operating activities was $317,~~254~~

~~352~~317

95 during the year ended December 31,~~271~~ 2023, as compared to $

~~decrease of $98~~164,~~341 for the year ended December 31, 2021~~714

for the year ended December 31, 2022. The

widening in

net cash used in operating activities in the amount of $152,

603

was primary attributable to no significant impairments in assets be recorded

, bad debts recovered offset to increase in accrued expenses

for year ended December 31, 2023.

Net cash used in investing activities was $1,834 during the year ended December 31, 2023, as compared to $

19,193

for the year ended December 31, 2022

, a reduction

in net cash used in investing activities.

Net cash provided by financing activities was $361,735 during the year ended December 31, 2023, as compared to $

180,146

for the year ended December 31, 2022. The increase in net cash provided by financing activities was due to the proceeds from related party.

As a result of the above factors, net decrease in cash and cash equivalents was $3,862 for the year ended December 31, 2023, as compared to net

decrease of $5,972 for the year ended December 31, 2022

Going concern

Our auditors have issued a “going concern” opinion, meaning that there is substantial doubt if we can continue as an on-going business for the next twelve months unless we obtain additional capital or generate sufficient revenues to fund for our operation.

The Company requires additional funding to meet its ongoing obligations and to fund its operations. Our auditor has expressed substantial doubt about our ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on generating revenues and raising capital to fund its business operations. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty.

Critical Accounting Policies

Principles of Consolidation

The accompanying consolidated financial statements, including the accounts of EOS Inc. and its wholly owned subsidiaries in Taiwan, British Virgin Islands, and People’s Republic of China, have been prepared in conformity with accounting principles generally accepted in the United States of America. Since the Company and Emperor Star are entities under common control prior to the acquisition of Emperor Star, the transaction is accounted for as a restructuring transaction. All assets and liabilities of Emperor Star were transferred to the Company at their respective carrying amounts on the date of transaction. The Company has recast prior period financial statements to reflect the conveyance of Emperor Star’s common shares as if the restructuring transaction had occurred as of the earliest date of the consolidated financial statements. All material intercompany accounts, transactions, and profits have been eliminated in consolidation. The nature of and effects on earnings per share (EPS) of non-recurring intra-entity transactions involving long-term assets and liabilities is not required to be eliminated and EPS amounts have been recast to include the earnings (or losses) of the transferred net assets.

The functional currency of the subsidiaries in Taiwan is the New Taiwan dollars and the subsidiary in People’s Republic of China is the Chinese Yuan, or Renminbi; however, the accompanying consolidated financial statements have been translated and presented in United States Dollars ($). In the accompanying consolidated financial statements and notes, “$”, “US$” and “U.S. dollars” mean United States dollars, “NT$” and “NT dollars” mean New Taiwan dollars, and “RMB” means Chinese Yuan, or Renminbi.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents include cash and all highly liquid instruments with original maturities of three months or less.

Accounts Receivable

Accounts receivable ~~are~~is stated at carrying value less estimates made for doubtful receivables. An allowance for impairment of trade receivables is established if the collection of a receivable becomes doubtful. Such receivable becomes doubtful when there is objective evidence that the Company will not be able to collect all amounts due according to the original terms of the receivables. Significant financial difficulties of the debtor, probability that the debtor will enter into bankruptcy or financial reorganization, and default or delinquency in payments are considered indicators that the receivable is impaired. The amount of the allowance is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. An impairment loss is recognized in the statement of income, as are subsequent recoveries of previous impairments.

Inventory

Inventory is stated at the lower of cost and net realizable value. Net realizable value (NRV) is defined as estimated selling prices less costs of completion, disposal, and transportation. Inventory consists mainly of finished goods held for resale. Cost is determined on a weighted average cost method. The Company periodically reviews the age and turnover of its inventory to determine whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory obsolescence.

Property and Equipment

Property and equipment are carried at cost net of accumulated depreciation. Expenditures that improve the functionality of the related asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment under capital leases, generally over five years. Depreciation expense was $~~3,257 and $1,887 for the years ended December 31, 2022 and 2021, respectively. Impairment loss was $17,381 and $nil for the years ended December 31, 2022 and 2021, respectively.~~

833

and $3,257 for the years ended December 31, 2023 and 2022, respectively. Impairment loss was $

and $17,381 for the years ended December 31, 2023 and 2022, respectively.

Impairment of Long-Lived Assets

The Company has adopted Accounting Standards Codification subtopic 360-10, Property, Plant and Equipment (“ASC 360-10”). ASC 360-10 requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavourable changes in business conditions, recurring losses, or a forecasted inability to achieve breakeven operating results over an extended period. The Company evaluates the recoverability of long-lived assets based upon forecasted undiscounted cash flows. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell. Impairment loss on property and equipment was $~~17,381 and $nil for the years ended December 31, 2022 and 2021, respectively.~~

1127

and $17,381 for the years ended December 31, 2023 and 2022, respectively.

Revenue Recognition

Pursuant to ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Merchandise sales: The Company recognizes sales revenues from merchandise sales when customers obtain control of the Company’s products, which typically occurs upon delivery to customer. Merchandise sales revenues are recorded at the sales price, or “transaction price”.

Software sales: The Company does not develop the software products on its own. When the Company receives a purchase order from the customer, the Company would engage with the third-party software company to customize and develop the software products. The Company recognizes software revenues upon completion of the installation and testing, and transfer the control of the software products to the customer. Software revenues are recorded at the fixed sales price, or “transaction price”, pursuant to the sales contracts. The Company may also charge the customer maintenance service fees on a straight-line basis over the service period pursuant to the sales contract. The Company concluded that the performance obligation for the maintenance service is distinct. Therefore, such maintenance service revenue can be separated from other elements in the arrangement.

Trade discount and allowances: The Company generally does not provide invoice discounts on product sales to its customers for prompt payment.

Product returns: The Company generally does not provide customers with the right to return a product for a full or partial refund, a credit, or an exchange for another product.

To date, product allowance and returns have been minimal and, based on its experience, the Company believes that returns of its products will continue to be minimal.

Since COVID-19 pandemic hit globally in 2020 and throughout first three quarters of financial year ended December 31, 2021, management assessed that the market conditions that it operated in was worsening. Credit risk on customers was determined to have deteriorated significantly as the majority of its customers were located in the PRC. Accordingly, management took the position that revenue would only be recognized when the consideration is received as to satisfy revenue recognition criteria related to reasonable certainty of collections.

During the fourth quarter of financial year ended December 31, 2021, the Covid pandemic was effectively controlled in the PRC. Management re-assessed the market conditions and determined that the overall market conditions were improving, and the Company’s collection history in the prior three quarters was positive, and in fourth quarter of 2021 reached sustainable recovery rate comparable to pre-COVID-19 environment. Accordingly, management decided that due to the improved conditions collection is now reasonably certain, and revenue is now recognized when risk and rewards are transferred to its customers.

Leases

The Company adopted FASB Accounting Standards Codification, Topic 842, Leases (“ASC 842”) using the modified retrospective approach, electing the practical expedient that allows the Company not to restate its comparative periods prior to the adoption of the standard on January 1, 2019. As such, the disclosures required under ASC 842 are not presented for periods before the date of adoption. For the comparative periods prior to adoption, the Company presented the disclosures which were required under ASC 842.

The new leasing standard requires recognition of leases on the consolidated balance sheets as right-of-use (“ROU”) assets and lease liabilities. ROU assets represent the Company’s right to use underlying assets for the lease terms and lease liabilities represent the Company’s obligation to make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value and future minimum lease payments over the lease term at commencement date. The Company’s future minimum based payments used to determine the Company’s lease liabilities mainly include minimum based rent payments. As most of Company’s leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.

In addition, the adoption of the standard did not have a material impact on the Company’s results of operations or cash flows. Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term and is recorded in Selling, general and administrative expenses. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which the variable lease payments are based occur.

1314

Advertising Costs

Advertising costs are expensed at the time such advertising commences. Advertising expenses were $1~~,966 and $399 for the years ended December 31, 2022 and 2021, respectively.~~

and $1,966 for the years ended December 31, 2023 and 2022, respectively.

Stock-Based Compensation

The Company accounts for stock-based compensation in accordance with ASC 718, Compensation-Stock Compensation (“ASC 718”). Under the fair value recognition provisions, stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as compensation expense on a straight-line basis over the requisite service period, based on the terms of the awards. The Company calculates the fair value of option grants utilizing the Black-Scholes pricing model and estimates the fair value of the stock based upon the estimated fair value of the common stock.

In June 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”). ASU 2018-07 expands the guidance in ASC 718 to include share-based payments for goods and services to non-employees and generally aligns it with the guidance for share-based payments to employees. In accordance with ASU 2018-07, these stock options and warrants issued as compensation for services provided to the Company are accounted for based upon the fair value of the underlying equity instrument. The fair value of the equity instrument is charged directly to compensation expense and additional-paid-in capital over the period during which services are rendered.

Post-retirement and Post-employment Benefits

The Company’s subsidiaries in Taiwan adopted the government mandated defined contribution plan pursuant to the Taiwan Labor Pension Act (the “Act”). Such labor regulations require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of the worker’s monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees’ salaries to the employees’ pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee benefits, which were expensed as incurred, were $~~5,233 and $5,873 for the years ended December 31, 2022 and 2021, respectively. Other than the above, the Company does not provide any other post-retirement or post-employment benefits.~~

676

and $5,233 for the years ended December 31, 2023 and 2022, respectively. Other than the above, the Company does not provide any other post-retirement or post-employment benefits.

Fair Value Measurements

FASB ASC 820, “Fair Value Measurements” defines fair value for certain financial and non-financial assets and liabilities that are recorded at fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes the inputs into three broad levels based on the reliability of the inputs as follows:

1415

Level 1 – Inputs are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available.

Level 2 – Inputs other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Valuations based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset or liability.

The carrying values of certain assets and liabilities of the Company, such as cash and cash equivalents, accounts receivable, inventory, advance to suppliers, prepaid expenses, accounts payable, accrued expenses, and due to shareholders, approximate fair value because of to their relatively short maturities. 

Earnings (Loss) Per Share

Basic income (loss) per share is computed by dividing net income (loss) by weighted average number of shares of common stock outstanding during each period. Diluted income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock, common stock equivalents, and potentially dilutive securities outstanding during each year. Dilutive shares are excluded the exercise price is greater than the average market price and when the Company incurred a net loss as the inclusion of such shares would have an anti-dilutive effect.

For the years ended December 31, ~~2022~~2023 and ~~2021~~2022, warrants were excluded as dilutive shares as the Company incurred a net loss.

Income Taxes

The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which requires that the Company recognize deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax basis of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when, in the opinion of management, it is more likely than not that some or all of any deferred tax assets will not be realized.

Foreign-currency Transactions

Foreign-currency transactions are recorded in New Taiwan dollars (“NTD”) and Renminbi (“RMB”) at the rates of exchange in effect when the transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency is converted into New Taiwan dollars and Renminbi, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of conversion or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated investments in shares of stock where such differences are accounted for as translation adjustments under stockholders’ equity.

1516

Translation Adjustment

The accounts of the Company’s subsidiaries were maintained, and their financial statements were expressed in New Taiwan Dollar (“NTD”) and Chinese Yuan, or Renminbi (“RMB”). Such financial statements were translated into U.S. Dollars (“$” or “USD”) in accordance ASC 830, “Foreign Currency Matters”, with the NTD and RMB as the functional currency. According to the Statement, all assets and liabilities are translated at the current exchange rate, common stock and additional paid-in capital are translated at the historical rates, and income statement items are translated at an average exchange rate for the period. The resulting translation adjustments are reported under accumulated other comprehensive income (loss) as a component of stockholders’ equity.

Comprehensive Income (loss)

Comprehensive income (loss) includes accumulated foreign currency translation gains and losses. The Company has reported the components of comprehensive income (loss) on its consolidated statements of operations and other comprehensive income (loss).

Concentration of Credit Risk

Cash and cash equivalents

: The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions in Taiwan, but these investments may be in excess of the insurance limits of Taiwan Central Deposit Insurance Corporation (the “TCDIC”). The Company does not enter into financial instruments for hedging, trading or speculative purposes. Concentration of credit risk with respect to trade and notes receivables is limited due to the wide variety of customers and markets in which the Company transacts business, as well as their dispersion across many geographical areas. As of December 31, 2023 and 2022, the Company had approximately $nil and $nil in excess of TCDIC insured limits. The Company has not experienced any losses in such accounts.

: The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions in Taiwan, but these investments may be in excess of the insurance limits of Taiwan Central Deposit Insurance Corporation (the “TCDIC”). The Company does not enter into financial instruments for hedging, trading or speculative purposes. Concentration of credit risk with respect to trade and notes receivables is limited due to the wide variety of customers and markets in which the Company transacts business, as well as their dispersion across many geographical areas. As of December 31, 2022 and 2021, the Company had approximately $nil and $nil in excess of TCDIC insured limits. The Company has not experienced any losses in such accounts.

Customers

: The Company performs ongoing credit evaluations of its customers’ financial condition and generally requires no collateral.

Recent Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments.” This pronouncement, along with subsequent ASUs issued to clarify provisions of ASU 2016-13, changes the impairment model for most financial assets and will require the use of an “expected loss” model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. In developing the estimate for lifetime expected credit loss, entities must incorporate historical experience, current conditions, and reasonable and supportable forecasts. This pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019. On November 19, 2019, the FASB issued ASU No. 2019-10, Financial Instruments—Credit Losses (Topic 326), finalized various effective date delays for private companies, not-for-profit organizations, and certain smaller reporting companies applying the credit losses (CECL), the revised effective date is January 2023.[

for auditor’s review ]

Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on our condensed financial statements.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as of December 31, ~~2022~~2023.

~~Item 7A. Quantitative and Qualitative Disclosures about Market Risk.~~I

tem 7A. Quantitative and Qualitative Disclosures about Market Risk.

Not applicable to smaller reporting companies.

~~Item 8. Financial Statements and Supplementary Data.~~I

tem 8. Financial Statements and Supplementary Data.

FINANCIAL STATEMENT SCHEDULES

Report of Independent Registered Public Accounting Firm (PCAOB ID: 6732)	F-2
Financial Statements:
Consolidated Balance Sheets	F-3
Consolidated Statements of Operations and Comprehensive Loss	F-4
Consolidated Statements of Stockholders’ Equity	F-5
Consolidated Statements of Changes in Shareholders' Deficit	F-5
Consolidated Statements of Cash Flows	F-6
Notes to Consolidated Financial Statements	F-7

F-1

~~REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM~~R

EPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of EOS Inc.:

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of EOS Inc. together with its subsidiaries (the “Company”) as of December 31, 2023 and 2022, and the related consolidated statements of operation and comprehensive loss, stockholders' ~~equity~~deficit, and cash flows for each of the ~~year~~two years in the period ended December 31, ~~2022~~2023, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the ~~year~~two years in the period ended December 31, ~~2022~~2023, in conformity with accounting principles generally accepted in the United States.

Going Concern Uncertainty

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has net ~~losses~~loss, negative working capital and accumulated deficit that raise substantial doubt about its ability to continue as a going concern. Management’s plans regarding these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Emphasis of Matter

The Company has significant transactions with related parties, which are described in Note 5 to the financial statements. Transactions involving related parties cannot be presumed to be carried out on an arm’s length basis, as the requisite conditions of competitive, free market dealings may not exist.

/s/

Onestop Assurance PAC

We have served as the Company’s auditor since 2021.

Singapore

~~March~~April ~~31, 2023~~16

, 2024

F-2

EOS, INC. AND SUBSIDIARIES

~~Consolidated Balance Sheets~~C

Asonsolidated ofBalance ~~December 31, 2022 and 2021~~Sheets

	December 31, 2022			December 31, 2021
ASSETS
Current Assets
Cash and cash equivalents		18,169			24,141
Accounts receivable		160,253			548,201
Inventory, net		46,196			29,573
Advances to suppliers		166,594			280,224
Security deposits		6,608			1,127,989
Prepaid expenses and other current assets		28,096			27,773
Total Current Assets		425,916			2,037,901
Non-Current Assets
Property, plant and equipment, net		4,692			6,739
Operating lease right of use asset		115,884			85,419
Total Non-Current Assets		120,576			92,158
Total Assets		546,492			2,130,059
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities
Accounts payable		-			-
Other payable and accrued expenses		73,352			88,040
Due to shareholders		277,080			30,858
Income taxes payable		49,074			55,394
Other current liabilities		750,000			500,000
Operating lease liabilities - current		48,231			37,779
Current portion of long-term loan payables		68,497			80,047
Total Current Liabilities		1,266,234			792,118
Non-Current Liabilities
Long-term loan payables		116,012			204,133
Operating lease liabilities - non-current		80,538			47,640
Total Non-Current Liabilities		196,550			251,773
Total Liabilities		1,462,784			1,043,891
Commitments and Contingencies		-			-
Shareholders’ Equity
Preferred stock ($0.001 par value, 5,000,000 shares authorized, 1,500,000 shares issued and outstanding as of December 31, 2022 and 2021, respectively)		1,500			1,500
Common stock ($0.001 par value; 575,000,000 shares authorized, 183,781,560 and 180,065,254 shares issued and outstanding as of December 31, 2022 and 2021, respectively)		183,781			180,065
Additional paid in capital		67,249			29,060
Deferred stock compensation		(40,674	)		-
Accumulated income (loss)		(1,165,665	)		722,925
Accumulated other comprehensive loss		42,964			133,056
Total equity attributable to EOS, Inc.		(910,845	)		1,066,606
Non-controlling interest		(5,447	)		19,562
Total Equity		(916,292	)		1,086,168
Total Liabilities and Shareholders’ Equity		546,492			2,130,059

As of December 31, 2023 and 2022

	December 31, 202 3			December 31, 202 2
ASSETS
Current Assets
Cash and cash equivalents	$	14,307		$	18,169
Accounts receivable		224,590			160,253
Inventory, net		79,482			46,196
Advances to suppliers		161,179			166,594
Security deposits		3,802			6,608
Prepaid expenses a nd other current assets		3,959			28,096
Total Current A ssets	$	487,319		$	425,916
Non-Current Assets
Property, plant and equipment, net	$	5,660		$	4,692
Operating lease right of use asset		4,192			115,884

Total Non-Current Assets	$	9,852		$	120,576
Total A ssets	$	497,171		$	546,492
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities
Accounts payable	$	9,761		$	-
Other payable and accrued expenses		309,103			73,352
Due to sh a reholders		74,065			277,080
Income taxes payable		45,318			49,074
Other current liabilities		1,000,000			750,000
Operating lease liabilities - current		2,818			48,231
Current portion of long-term loan payables		53,165			68,497
Total Current Liabilities	$	1,494,230		$	1,266,234
Non-Current Liabilities
Long-term loan payables	$	65,210		$	116,012
Operating lease liabilities - non-current		1,374			80,538
Total Non-Current Liabilities	$	66,584		$	196,550
Total Liabilities	$	1,560,814		$	1,462,784

Commitments and Contingencies	$	-		$	-

Shareholders’ Deficit
Preferred stock ($0.001 par value, 5,000,000 shares authorized, 1,500,000 shares issued and outstanding as of December 31, 2023 and 2022, respectively)	$	1,500		$	1,500
Common stock ($0.001 par value; 1,000,000,000 shares authorized, 604,781,560 and 183,781,560 shares issued and outstanding as of December 31, 2023 and 2022, respectively)		604,781			183,781
Additional paid in capital		175,268			67,249
Deferred stock compensation		(40,674	)		(40,674	)
Accumulated l oss		(1,802,695	)		(1,165,665	)
Accumulated other comprehensive income ( loss )	$	(1,823	)	$	42,964
Total deficit attributable to EOS, Inc.	$	(1,063,643	)	$	(910,845	)
Non-controlling interest	$	-		$	(5,447	)
Total Deficit	$	(1,063,643	)	$	(916,292	)
Total Liabilities and Shareholders’ Deficit	$	497,171		$	546,492

F-3

EOS, INC. AND SUBSIDIARIES

~~Consolidated Statements of Operation and Comprehensive Loss~~C

1onsolidated Statements of Operation and Comprehensive Loss

	Year ended December 31, 2022			Year ended December 31, 2021
Net sales	$	652,547		$	518,487
Cost of sales		365,282			312,951
Gross profit		287,265			205,536
Selling, general and administrative expenses		2,208,876			1,274,616
Income (Loss) from operations		(1,921,611	)		(1,069,080	)
Other income (expense)
Interest income (expense)		(4,512	)		(1,797	)
Other income (expense)		3,871			(49,238	)
Gain (loss) on investment in equity securities		-			35,142
Total other income (expense)		(641	)		(15,893	)
Loss before income tax provision		(1,922,252	)		(1,084,973	)
Income tax expenses (benefits)		(10,093	)		16,592
Net Loss	$	(1,912,159	)	$	(1,101,565	)
Other Comprehensive Income (Loss):
Net income (loss) attributable to non-controlling interests		(41,294	)		(21,231	)
Net income (loss) attributable to EOS and subsidiaries		(1,870,865	)		(1,080,334	)
Foreign currency translation adjustment, net of tax		(91,532	)		21,768
Comprehensive loss	$	(2,003,691	)	$	(1,079,797	)
Net loss per share:
Basic and diluted		(0.01	)		(0.01	)
Weighted average number of common shares:
Basic and diluted		182,376,491			77,243,336

For the Years Ended December 31, 2023 and 2022

	Year ended December 31, 202 3			Year ended December 31, 20 22
Net sales	$	296,852		$	652,547

Cost of sales		(102,975	)		(365,282	)

Gross profit		193,877			287,265

Selling, general and administrative expenses		(966,486	)		(2,208,876	)

Loss from operations		(772,609	)		(1,921,611	)

Other income (expense)
Interest expense		(6,859	)		(4,512	)
Other income		147,532			3,871

Tot a l other income (expense)		140,673			(641	)

Loss before income tax provision		(631,936	)		(1,922,252	)

Income tax benefits (expenses)		-			10,093

Net Loss	$	(631,936	)	$	(1,912,159	)

Other Comprehensive Loss:
Net l oss attributable to non-controlling interests		(4,782	)		(41,294	)
Net l oss attributable to EOS and subsidiaries		(627,154	)		(1,870,865	)
Foreign currency translation adjustment, net of tax		(44,434	)		(91,532	)
Comprehensive loss	$	(676,370	)	$	(2,003,691	)

Net loss per share:
Basic and diluted		(0.00	)		(0.01	)

Weighted average number of common shares:
Basic and diluted		219,639,094			182,376,491

F-4

EOS, INC. AND SUBSIDIARIES

Consolidated Statements of Changes in Shareholders’ ~~Equity~~

~~For the Years Ended December 31, 2022 and 2021~~Deficit

	Common Stock						Preferred Stock				Deferred			Additional						Accumulated other			Equity attributable			Non-
	Number of Shares			Amount			Number of Shares		Amount		Stock Compensation			Paid-in Capital			Retained Earnings			Comprehensive Income (Loss)			to EOS, Inc.			Controlling interest			Total Equity
Balance at December 31, 2020		74,123		$	74			-	$	-	$	-		$	186,474		$	1,803,259		$	111,776		$	2,101,583		$	40,305		$	2,141,888
Cancellation of Common Stock		(10,000	)		(10	)		-		-		-			(35,132	)		-			-			(35,142	)		-			(35,142	)
Reverse Stock Split Adjustment		1,131			1			-		-		-			(1	)		-			-			-			-			-
Shares Issued for Liability Converted		90,000,000			90,000			-		-		-			(30,781	)		-			-			59,219			-			59,219
Shares Issued for minority controlling interests of its subsidiary		90,000,000			90,000			-		-		-			(90,000	)		-			-			-			-			-
Issuance of Preferred Stock to related party		-			-			1,500,000		1,500		-			(1,500	)		-			-			-			-			-
Foreign currency translation adjustment		-			-			-		-		-			-			-			21,280			21,280			488			21,768
Net loss		-			-			-		-		-			-			(1,080,334	)		-			(1,080,334	)		(21,231	)		(1,101,565	)
Balance at December 31, 2021		180,065,254			180,065			1,500,000		1,500		-			29,060			722,925			133,056			1,066,606			19,562			1,086,168
Balance at December 31, 2021		180,065,254			180,065			1,500,000		1,500		-			29,060			722,925			133,056			1,066,606			19,562			1,086,168
Share issued for compensation		115,000			115			-		-		-			1,116			-			-			1,231			-			1,231
Deferred compensation expense relating to issuance of restricted common stock		3,601,306			3,601			-		-		(38,534	)		34,933			-			-			-			-			-
Deferred compensation expense relating to issuance of warrant		-			-			-		-		(2,140	)		2,140			-			-			-			-			-
Foreign currency translation adjustment		-			-			-		-		-			-			-			(90,092	)		(90,092	)		(1,440	)		(91,532	)
Net loss		-			-			-		-		-			-			(1,888,590	)		-			(1,888,590	)		(23,569	)		(1,912,159	)
Balance at December 31, 2022		183,781,560			183,781			1,500,000		1,500		(40,674	)		67,249			(1,165,665	)		42,964			(910,845	)		(5,447	)		(916,292	)

For the Years Ended December 31, 2023 and 2022

	Common Stock				Preferred Stock				Deferred			Additional					Accumulated other			Deficit attributable			Non-
	Number of Shares		Amount		Number of Shares		Amount		Stock Compensation			Paid-in Capital		Accum ulated loss			Comprehensive Income (Loss)			to EOS, Inc.			Controlling interest			Total Deficit
Balance at December 31, 202 1		180,065,254	$	180,065		1,500,000	$	1,500	$	-		$	29,060	$	722,925		$	133,056		$	1,066,606		$	19,562		$	1,086,168
Share issued for compensation		115,000		115		-		-		-			1,116		-			-			1,231			-			1,231
Deferred compensation expense relating to issuance of restricted common stock		3,601,306		3,601		-		-		(38,534	)		34,933		-			-			-			-			-
Deferred compensation expense relating to issuance of warrant		-		-		-		-		(2,140	)		2,140		-			-			-			-			-
Foreign currency translation adjustment		-		-		-		-		-			-		-			(90,092	)		(90,092	)		(1,440	)		(91,532	)
Net loss		-		-		-		-		-			-		(1,888,590	)		-			(1,888,590	)		(23,569	)		(1,912,159	)
Balance at December 31, 2022		183,781,560		183,781		1,500,000		1,500		(40,674	)		67,249		(1,165,665	)		42,964			(910,845	)		(5,447	)		(916,292	)

Balance at December 31, 2022		183,781,560		183,781		1,500,000		1,500		(40,674	)		67,249		(1,165,665	)		42,964			(910,845	)		(5,447	)		(916,292	)
Share issued for compensation		21,000,000		21,000		-		-		-			20,019		-			-			41,019			-			41,019
Shares issued at Debt Conversion		345,000,000		345,000		-		-		-			75,900		-			-			420,900			-			420,900
Shares issued at Debt Conversion		55,000,000		55,000		-		-		-			12,100		-			-			67,100			-			67,100
Foreign currency translation adjustment		-		-		-		-		-			-		-			(44,787	)		(44,787	)		353			(44,434	)
Net loss		-		-		-		-		-			-		(627,154	)		-			(627,154	)		(4,782	)		(631,936	)
Equity transaction within owners		-		-		-		-		-			-		(9,876	)		-			(9,876	)		9,876			-
Balance at December 31, 2023		604,781,560		604,781		1,500,000		1,500		(40,674	)		175,268		(1,802,695	)		(1,823	)		(1,063,643	)		-			(1,063,643	)

F-5

EOS, INC. AND SUBSIDIARIES

~~Consolidated Statements of Cash Flows~~C

~~For~~onsolidated ~~the~~Statements ~~Years~~of ~~Ended~~Cash ~~December 31, 2022 and 2021~~Flows

	Year ended December 31, 2022			Year ended December 31, 2021
Cash flows from operating activities
Net loss		(1,912,159	)		(1,101,565	)
Adjustments to reconcile net income to net cash provided by operating activities
Bad debt expenses		272,843			233,907
Depreciation		3,257			1,887
Amortization of right-of-use asset		26,296			27,963
Impairments of assets		1,060,300			-
Realized (gain) loss from investment		-			(35,142	)
Stock based compensation		1,231			-
Changes in assets and liabilities
Decrease (increase) in accounts receivable		88,021			341,157
Decrease (increase) in inventory		(20,006	)		186,455
Decrease (increase) in advance to suppliers		89,547			(85,318	)
Decrease (increase) in security deposits and other assets		(2,721	)		(950	)
Increase (decrease) in accounts payable		-			(18,524	)
Increase (decrease) in accrued expenses		243,517			255,542
Increase (decrease) in advances from customers		13,261			-
Increase (decrease) in income tax payable		(1,805	)		28,297
Increase (decrease) in operating lease liabilities		(26,296	)		(27,963	)
Net cash used in operating activities		(164,714	)		(194,254	)
Cash flows from investing activities
Purchase of equipment		(19,193	)		(352	)
Net cash used in investing activities		(19,193	)		(352	)
Cash flows from financing activities
Repayment to related party		-			(235,289	)
Proceeds from related party		254,835			216,467
Proceeds from borrowings		-			179,064
Repayment to borrowings		(74,689	)		(64,971	)
Net cash provided by financing activities		180,146			95,271
Effect of foreign currency translation on cash and cash equivalents		(2,211	)		994
Net decrease of cash and cash equivalents		(5,972	)		(98,341	)
Cash, cash equivalents, and restricted cash
Beginning		24,141			122,482
Ending	$	18,169		$	24,141
Supplemental Disclosure of Cash Flows
Cash paid during the periods for:
Interest	$	-		$	3,142
Income taxes	$	-		$	16,592
Non-cash financing and investing activities:
Related party debt converted to Common stock	$	-		$	59,219
Issuance of Common Stock for minority controlling interests of its subsidiary	$	-		$	90,000
Issuance of Preferred Stock to related party	$	-		$	1,500
Deferred compensation expense relating to issuance of restricted common stock	$	38,534		$	-
Deferred compensation expense relating to issuance of warrant	$	2,140		$	-

For the Years Ended December 31, 2023 and 2022

	Year ended December 31, 202 3			Year ended December 31, 202 2
Cash flows from operating activities
Net loss		(631,936	)		(1,912,159	)
Adjustments to reconcile net income to net cash provided by operating activities
Bad debt expenses		-			272,843
Bad debt recovery		(148,452	)		-
Depreciation

Filing Compare · EOS INC.